Clinical trials · Riverside–San Bernardino, CA
Metastatic Castration-resistant Prostate Cancer clinical trials in Riverside–San Bernardino
We’re tracking 51 recruiting metastatic castration-resistant prostate cancer studies with a site in or near Riverside–San Bernardino — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3, Phase 3 and Phase 4 studies, each written for real people, not researchers.
Recruiting studies near Riverside–San Bernardino
- NCT07114601RecruitingPhase 1
Study of LY4257496 for people with GRPR-positive solid tumors
This trial tests a new drug, LY4257496, in people with certain types of cancer that have a protein called GRPR on their cells. The study aims to see if the drug can help shrink tumors or slow the cancer's growth.
Duarte, CaliforniaAges 18 years+ - NCT05107674RecruitingPhase 1
Early drug study for advanced cancers that have limited options
This Phase 1 study tests NX-1607 in adults with advanced cancers that are hard to treat with standard care. It focuses on safety and early signs of how well the drug may work in specific cancer types.
Duarte, CaliforniaAges 18 years+ - NCT06217822RecruitingPhase 1
Testing a new radiation therapy for advanced prostate cancer
This trial tests a new radioactive drug, 225Ac-PSMA-Trillium, that targets prostate cancer cells. It is for people whose advanced prostate cancer has stopped responding to hormone therapy and may have spread.
Duarte, CaliforniaAges 18 years+ - NCT05534646RecruitingPhase 2
Apalutamide plus a cancer antibody for spreading prostate cancer
This Phase 2 study tests apalutamide combined with a targeted antibody (carotuximab) for prostate cancer that is still growing despite hormone treatment. It may help slow tumor growth by blocking cancer signals in different ways.
Duarte, CaliforniaAges 18 years+ - NCT06267729RecruitingPhase 1/Phase 2
A new cell therapy for advanced prostate cancer
This trial tests a new cell therapy (AZD0754) for metastatic prostate cancer that has stopped responding to standard hormone therapy and chemotherapy. It’s looking for people whose cancer has gotten worse despite prior treatments, and who are still in fairly good health.
Duarte, CaliforniaAges 18–130 - NCT04986423RecruitingPhase 2
Add ZEN003694 to enzalutamide for resistant prostate cancer
This Phase 2 study tests whether adding ZEN003694 to enzalutamide works better than enzalutamide alone in men whose prostate cancer has spread and is no longer controlled by hormone lowering treatments. It focuses on people who either did not respond well to abiraterone (poor responders) or did respond (responders), then compares outcomes between treatment groups.
Whittier, CaliforniaAges 18 years+ - NCT06785636RecruitingPhase 1/Phase 2
New drug combination for advanced prostate cancer
This study tests a new drug (pocenbrodib) alone or combined with another hormone therapy (darolutamide) for men with advanced prostate cancer that has spread. It is for those who have already tried Pluvicto and one other hormone therapy, but not yet chemotherapy.
Fountain Valley, CaliforniaAges 18 years+ - NCT05519449RecruitingPhase 1
Testing a PSMA-targeting treatment for advanced prostate cancer
This Phase 1 trial tests JANX007 in men with metastatic castration-resistant prostate cancer (cancer that keeps growing despite standard hormone treatment). It aims to find a safe dose and see whether the treatment can shrink tumors or slow progression.
Newport Beach, CaliforniaAges 18–100 - NCT07590934RecruitingPhase 1/Phase 2
Testing new cancer drugs for advanced prostate cancer
This study tests new anti-cancer drugs for men whose prostate cancer has spread and stopped responding to hormone therapy. The goal is to find treatments that work when standard drugs no longer help.
South Pasadena, CaliforniaAges 18–99 - NCT04787744RecruitingPhase 2/Phase 3
Test standard prostate cancer treatment with or without targeted spot radiation
This study tests whether adding targeted local treatment (like radiation to a few spots seen on scans) improves outcomes for some people with limited (oligometastatic) prostate cancer. It compares standard systemic therapy alone versus standard therapy plus PET-scan–guided spot treatment.
Long Beach, CaliforniaAges 18 years+ - NCT06470243RecruitingPhase 3
Adding carboplatin to cabazitaxel for advanced prostate cancer
This study tests whether adding a chemotherapy drug called carboplatin to another chemotherapy called cabazitaxel works better than cabazitaxel alone for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. All participants must have already had docetaxel chemotherapy.
Long Beach, CaliforniaAges 18 years+ - NCT06842498RecruitingPhase 2
FG-3246 for advanced prostate cancer
This trial tests a new drug called FG-3246, which targets a protein (CD46) on prostate cancer cells. It's for men with advanced prostate cancer that has spread and stopped responding to standard hormone therapy, and who have had limited prior treatments.
Los Angeles, CaliforniaAges 18 years+ - NCT04606446RecruitingPhase 2
Study drug for ER-positive, HER2-negative cancers after treatment
This Phase 2 study tests a new Pfizer medicine (PF-07248144) for certain advanced or metastatic breast, prostate, or lung cancers that have not responded to standard treatment or no standard options exist. You may qualify if you have a specific tumor type and a limited number of prior cancer treatments, and if your body functions (blood, liver, kidneys) and heart rhythm meet safety limits.
Los Angeles, CaliforniaAges 18 years+ - NCT07164443RecruitingPhase 3
Study comparing pasritamig to placebo for advanced prostate cancer
This trial tests a new drug called pasritamig against a placebo for people with advanced prostate cancer that has stopped responding to hormone therapy and chemotherapy. The goal is to see if pasritamig can help slow the cancer's growth.
Los Angeles, CaliforniaAges 18 years+ - NCT05919264RecruitingPhase 1/Phase 2
FOG-001 for advanced solid tumors with certain gene changes
This trial tests a new drug, FOG-001, alone or with other treatments, for people with advanced solid tumors that have specific changes in the WNT pathway genes. It aims to see if the drug can shrink tumors or slow their growth.
Los Angeles, CaliforniaAges 18 years+ - NCT05398302RecruitingPhase 1
Biopsies during prostate cancer treatment to study resistance
This early study uses image-guided biopsies (small tissue samples taken with imaging) to learn why metastatic prostate cancer may stop responding to PSMA radioligand therapy. The results may help doctors understand resistance and improve future treatments.
Los Angeles, CaliforniaAges Any age - NCT06531499RecruitingPhase 1
Study of a radioactive drug for advanced prostate cancer
This trial tests an extended treatment with a radioactive drug (177Lu-PSMA-617) to see how the body handles it, how safe it is, and how well it works. It is for men with metastatic castration-resistant prostate cancer who have not had chemotherapy yet.
Los Angeles, CaliforniaAges 18–100 - NCT06228053RecruitingPhase 2
Study of SX-682 plus enzalutamide for men with advanced prostate cancer
This trial tests whether adding the drug SX-682 to enzalutamide can help men whose prostate cancer has stopped responding to other hormone treatments. You may be eligible if your cancer is growing despite treatment with abiraterone, darolutamide, apalutamide, or enzalutamide.
Los Angeles, CaliforniaAges 18 years+ - NCT06288113RecruitingPhase 2
Re-treatment with 177Lu-PSMA-617 for prostate cancer
This trial tests if a second round of a targeted radiation therapy (177Lu-PSMA-617) can help men whose prostate cancer has returned after a successful first treatment. It is for men whose cancer has stopped responding to hormone therapy and chemotherapy, and whose PSA levels have risen again after a prior good response to this drug.
Los Angeles, CaliforniaAges Any age - NCT07287150RecruitingPhase 2
Inavolisib for metastatic castration-resistant prostate cancer
This trial tests a new drug called Inavolisib for men with a specific type of advanced prostate cancer that has stopped responding to hormone therapy. It aims to see if the drug can help slow the cancer's growth.
Los Angeles, CaliforniaAges 18 years+ - NCT06706921RecruitingPhase 4
Predicting treatment success with PET scans in prostate cancer
This study looks at whether a special PET scan can help predict how well a targeted radiation therapy (LuPSMA) works in men with advanced prostate cancer that has spread. You would get several PET scans before and after treatment to see if the scan results can forecast your outcome.
Los Angeles, CaliforniaAges 18 years+ - NCT05489211RecruitingPhase 2
Testing a cancer drug for advanced solid tumors
This Phase 2 study tests the drug Dato-DXd (alone or with other cancer medicines) in people with advanced solid tumors. It looks for tumor shrinkage and how safely the treatment can be given.
Los Angeles, CaliforniaAges 18–130 - NCT06353386RecruitingPhase 1/Phase 2
Opevesostat combinations for advanced prostate cancer
This study tests a new drug called opevesostat, alone or combined with other treatments, for men with advanced prostate cancer that has spread and stopped responding to hormone therapy. It aims to see if it can help control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06615752RecruitingPhase 1/Phase 2
Green tea and quercetin with chemo for prostate cancer
This trial tests whether adding green tea extract and quercetin (a plant compound) to standard chemotherapy (docetaxel) can help men with advanced prostate cancer that has stopped responding to hormone therapy. The goal is to see if this combination is safe and works better than chemo alone.
Los Angeles, CaliforniaAges 18 years+
Hear when a new Metastatic Castration-resistant Prostate Cancer trial opens near Riverside–San Bernardino, CA
We’ll email you when one opens near Riverside–San Bernardino, CA — at most once a week, no account needed, unsubscribe anytime.
Metastatic Castration-resistant Prostate Cancer trials in other cities
Where these studies are running near Riverside–San Bernardino
Institutions with a site for the recruiting metastatic castration-resistant prostate cancer studies listed above.
- University of California, Los Angeles (UCLA) · 7 studies
- City of Hope Comprehensive Cancer Center · 4 studies
- Cedars-Sinai Medical Center · 3 studies
- Research Site · 3 studies
- VA Greater Los Angeles Healthcare System · 3 studies
- UCLA / Jonsson Comprehensive Cancer Center · 2 studies
- California Research Institute
- Cancer and Blood Specialty Clinic
What taking part in a metastatic castration-resistant prostate cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting metastatic castration-resistant prostate cancer studies in California.
Common questions
- Are there metastatic castration-resistant prostate cancer clinical trials near Riverside–San Bernardino?
- Yes. We're currently tracking 51 recruiting metastatic castration-resistant prostate cancer studies with a site near Riverside–San Bernardino, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a metastatic castration-resistant prostate cancer study near Riverside–San Bernardino?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Riverside–San Bernardino to take part?
- Not necessarily. These studies have a site near Riverside–San Bernardino, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a metastatic castration-resistant prostate cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New metastatic castration-resistant prostate cancer studies open near Riverside–San Bernardino regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.